Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 865–888 of 3,526 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Saline (Placebo Control) Clear all
Withdrawn Not applicable Interventional

Intravenous Lidocaine and Quality of Recovery After Cesarean Delivery

NCT02257346
View directory record Official record
Conditions
Pregnancy
Interventions
Lidocaine, Normal Saline
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2022 · Synced Oct 20, 2026, 6:59 AM EDT
Enrolling by invitation Phase 1 Interventional

Immunologic and Virologic Parameters During Analytical Treatment Interruption Following Combination bNAb Therapy During Suppressive ART

NCT06908083
View directory record Official record
Conditions
HIV
Interventions
Analytical Treatment Interruption
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Bethesda, Maryland • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Fentanyl as an Analgesic for Cystoscopic Procedures

NCT01708122
View directory record Official record
Conditions
Pain
Interventions
Fentanyl, saline
Drug
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Aug 20, 2015 · Synced Oct 20, 2026, 6:59 AM EDT
Terminated Phase 1 Interventional

A Dose Escalation and Safety Study of I5NP to Prevent Acute Kidney Injury (AKI) in Patients at High Risk of AKI Undergoing Major Cardiovascular Surgery (QRK.004)

NCT00683553
View directory record Official record
Conditions
Acute Renal Failure, Acute Kidney Injury
Interventions
I5NP, Placebo
Drug
Lead sponsor
Quark Pharmaceuticals
Industry
Eligibility
21 Years to 85 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 16, 2010 · Synced Oct 20, 2026, 6:59 AM EDT
Terminated Phase 4 Interventional Results available

Esmolol Infusion During Laminectomy: Effect on Quality of Recovery

NCT01179113
View directory record Official record
Conditions
Laminectomy
Interventions
Esmolol, Saline
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 6:59 AM EDT
Withdrawn Phase 2 Interventional

Early Treatment With Dexamethasone in Mild Acute Pancreatitis

NCT01247961
View directory record Official record
Conditions
Patients With Acute Pancreatitis
Interventions
Dexamethasone acetate, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced Oct 20, 2026, 6:59 AM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Efficacy and Safety of NVX-CoV2705

NCT07086222
View directory record Official record
Conditions
COVID-19, Sars-CoV-2 Infection
Interventions
NVX-CoV2705, Placebo
Biological
Lead sponsor
Novavax
Industry
Eligibility
50 Years to 65 Years
Enrollment
6,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
99
States / cities
Athens, Alabama • Birmingham, Alabama • Gadsden, Alabama + 88 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 20, 2026, 6:59 AM EDT
Terminated Phase 3 Interventional Results available

Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer

NCT02049151
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
Tecemotide, Placebo, Cyclophosphamide (CPA), Saline (sodium chloride)
Drug
Lead sponsor
EMD Serono
Industry
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Rockland, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 23, 2017 · Synced Oct 20, 2026, 6:59 AM EDT
Terminated Phase 2 Interventional Results available

Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus

NCT02452528
View directory record Official record
Conditions
Chronic Hepatitis B
Interventions
ARC-520, Placebo, Entecavir, Tenofovir, diphenhydramine
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
4
States / cities
San Francisco, California • Miami, Florida • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Oct 20, 2026, 6:59 AM EDT
Withdrawn Phase 2 Interventional

Safety and Efficacy of IONIS-FB-Lrx in up to 120 Patients 55 and Older With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)

NCT03446144
View directory record Official record
Conditions
Geographic Atrophy, Age Related Macular Degeneration
Interventions
IONIS-FB-Lrx, Placebo (sterline saline 0.9%)
Drug
Lead sponsor
Ionis Pharmaceuticals, Inc.
Industry
Eligibility
55 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
24
States / cities
Phoenix, Arizona • Beverly Hills, California • Encino, California + 20 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ANX-188 Thorough QT/QTc Study in Healthy Volunteers

NCT01790087
View directory record Official record
Conditions
Healthy
Interventions
ANX-188 Therapeutic Dose, ANX-188 Supratherapeutic dose, Saline, Moxifloxacin
Drug
Lead sponsor
Mast Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 20, 2015 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 2 Interventional

Dendritic Cell Vaccine for Patients With Brain Tumors

NCT01204684
View directory record Official record
Conditions
Glioma, Anaplastic Astrocytoma, Anaplastic Astro-oligodendroglioma, Glioblastoma
Interventions
autologous tumor lysate-pulsed DC vaccination, Tumor lysate-pulsed DC vaccination+0.2% resiquimod, Tumor-lysate pulsed DC vaccination +adjuvant polyICLC
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 20, 2026, 6:59 AM EDT
Terminated Phase 4 Interventional Results available

Continuous Erector Spinae Plane Blocks for Rib Fractures

NCT04558281
View directory record Official record
Conditions
Rib Fractures, Trauma, Anesthesia, Anesthesia, Local
Interventions
Active ropivacaine 0.3% erector spinae plane perineural administration, Placebo erector spinae plane perineural administration
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT)

NCT03945292
View directory record Official record
Conditions
Alpha 1-Antitrypsin Deficiency
Interventions
Fazisiran Injection, Placebo
Drug · Other
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
16
States / cities
Birmingham, Alabama • Phoenix, Arizona • La Jolla, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Results available

Certolizumab Pegol for the Treatment of Patients With Active Rheumatoid Arthritis

NCT00717236
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab pegol (CZP), Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
1,648 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
101
States / cities
Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 98 more
Source: ClinicalTrials.gov public record
Updated Aug 1, 2018 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Ascending Multiple Dose Study of CD101 IV in Healthy Subjects

NCT02551549
View directory record Official record
Conditions
Healthy
Interventions
CD101 IV, Placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 26, 2017 · Synced Oct 20, 2026, 6:59 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Study of the Functional Magnetic Resonance Imaging Response to Leptin and Pramlintide

NCT00691158
View directory record Official record
Conditions
Obesity
Interventions
Pramlintide (Amylin), Placebo (Normal Saline), 2 Metreleptin, Leptin plus Pramlintide
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 45 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 16, 2022 · Synced Oct 20, 2026, 6:59 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Testosterone and Neural Function in Men With Spinal Cord Injury

NCT06130449
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Natesto testosterone intranasal gel, Ayr Saline Nasal Gel
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 80 Years · Male only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Not applicable Interventional

Efficacy of Hylenex in the Treatment of Pain Among Hospice Patients

NCT00547664
View directory record Official record
Conditions
Pain Management
Interventions
Hylenex recombinant , morphine, saline, Saline
Drug · Other
Lead sponsor
HPC Healthcare, Inc.
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
3
States / cities
Lakeland, Florida • Tampa, Florida • Temple Terrace, Florida
Source: ClinicalTrials.gov public record
Updated Feb 28, 2014 · Synced Oct 20, 2026, 6:59 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Study of OsrhAAT or Placebo in Healthy Volunteers

NCT05315921
View directory record Official record
Conditions
Emphysema Secondary to Congenital AATD
Interventions
OsrhAAT 1 mg/kg IV, OsrhAAT 3 mg/kg IV, OsrhAAT 10 mg/kg IV, OsrhAAT 20 mg/kg IV, OsrhAAT 40 mg/kg IV, OsrhAAT 60 mg/kg IV
Drug
Lead sponsor
Healthgen Biotechnology Corp.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Early Phase 1 Interventional

Effect of Enamel Matrix Proteins on Clinical Attachment Level and Alveolar Bone in Periodontal Maintenance Patients

NCT02972788
View directory record Official record
Conditions
Periodontal Bone Loss
Interventions
Enamel Matrix Proteins Derivative, Saline
Drug · Other
Lead sponsor
University of Nebraska
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Alpha1-Proteinase Inhibitor (Human), Modified Process (Alpha-1 MP) in Subjects With Pulmonary Emphysema Due to Alpha1 Antitrypsin Deficiency (AATD)

NCT01983241
View directory record Official record
Conditions
Pulmonary Emphysema in Alpha-1 PI Deficiency
Interventions
Alpha-1 MP, 0.9% Sodium Chloride for Injection, USP
Biological · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
10
States / cities
Phoenix, Arizona • Gainesville, Florida • Leesburg, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection

NCT00800605
View directory record Official record
Conditions
Influenza
Interventions
Vero cell-derived, trivalent, seasonal influenza vaccine, Placebo: Phosphate-buffered saline
Biological
Lead sponsor
Alachua Government Services, Inc.
Industry
Eligibility
18 Years to 49 Years
Enrollment
7,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
36
States / cities
Tucson, Arizona • Sacramento, California • San Diego, California + 31 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Oct 20, 2026, 6:59 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Gastrointestinal Sensorimotor Dysfunctions in Diabetes Mellitus

NCT02170870
View directory record Official record
Conditions
Dyspepsia, Diabetes Mellitus With Gastrointestinal Symptoms
Interventions
Exendin 9-39, Microlipid, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 20, 2026, 6:59 AM EDT